Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
S Qin, L Xu, M Yi, S Yu, K Wu, S Luo - Molecular cancer, 2019 - Springer
The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed
cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T …
cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T …
[HTML][HTML] Current status and future directions of cancer immunotherapy
H Zhang, J Chen - Journal of cancer, 2018 - ncbi.nlm.nih.gov
In the past decades, our knowledge about the relationship between cancer and the immune
system has increased considerably. Recent years' success of cancer immunotherapy …
system has increased considerably. Recent years' success of cancer immunotherapy …
Inter-and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling
Metastatic prostate cancer (mPC) comprises a spectrum of diverse phenotypes. However,
the extent of inter-and intra-tumor heterogeneity is not established. Here we use digital …
the extent of inter-and intra-tumor heterogeneity is not established. Here we use digital …
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial
Abstract B7 homolog 3 (B7-H3; CD276), a tumor-associated antigen and possible immune
checkpoint, is highly expressed in prostate cancer (PCa) and is associated with early …
checkpoint, is highly expressed in prostate cancer (PCa) and is associated with early …
[HTML][HTML] Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells
H Du, K Hirabayashi, S Ahn, NP Kren, SA Montgomery… - Cancer cell, 2019 - cell.com
The high expression across multiple tumor types and restricted expression in normal tissues
make B7-H3 an attractive target for immunotherapy. We generated chimeric antigen receptor …
make B7-H3 an attractive target for immunotherapy. We generated chimeric antigen receptor …
mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion
Identifying the mechanisms underlying the regulation of immune checkpoint molecules and
the therapeutic impact of targeting them in cancer is critical. Here we show that high …
the therapeutic impact of targeting them in cancer is critical. Here we show that high …
Clinical insights into novel immune checkpoint inhibitors
The success of immune checkpoint inhibitors (ICIs), notably anti-cytotoxic T lymphocyte
associated antigen-4 (CTLA-4) as well as inhibitors of CTLA-4, programmed death 1 (PD-1) …
associated antigen-4 (CTLA-4) as well as inhibitors of CTLA-4, programmed death 1 (PD-1) …
Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy
Importance There is a clear need for a molecular subtyping approach in prostate cancer to
identify clinically distinct subgroups that benefit from specific therapies. Objectives To …
identify clinically distinct subgroups that benefit from specific therapies. Objectives To …
The role of CD276 in cancers
S Liu, J Liang, Z Liu, C Zhang, Y Wang… - Frontiers in …, 2021 - frontiersin.org
Objective Aberrant expression of the immune checkpoint molecule, CD276, also known as
B7-H3, is associated with tumorigenesis. In this review, we aim to comprehensively describe …
B7-H3, is associated with tumorigenesis. In this review, we aim to comprehensively describe …
New B7 family checkpoints in human cancers
L Ni, C Dong - Molecular cancer therapeutics, 2017 - AACR
T cells are the main effector cells in immune response against tumors. The activation of T
cells is regulated by the innate immune system through positive and negative costimulatory …
cells is regulated by the innate immune system through positive and negative costimulatory …